An angel group that is made up entirely of healthcare professionals is seeking to invest in technologies that significantly advance the standard of care. The group considers companies at a range of stages and is geographically agnostic. Since the members are investing their own capital, the investment size and capital structure are highly flexible. The group is actively seeking new investment opportunities, and is open to leading financing rounds.
The group is interested in therapeutics, diagnostics, and medical devices. While the group will consider most any indication and technology type, the group currently has a particular interest in cell therapy and in the oncology sector. In general, the group is not interested in dermatology. The group will only consider products that have shown human clinical efficacy; in the case of therapeutics, the group generally looks at phase II companies but if a company has obtained human efficacy data in phase I, the group would consider the opportunity.
The group invests in both private and public companies. The group performs deep scientific due diligence on all the opportunities that the group takes part in, often conducted by the group’s members.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment